

GRILLO-LOPEZ - Appl. No. 09/762,587
Attorney Docket No. 037003-0277847

Amendments To The Claims

1.-6. (Canceled).

7. (Currently amended) A method for treating a subject having B-cell lymphoma, which subject is refractory to treatment with a non-radiolabeled ~~ehimeric~~ anti-CD20 antibody, comprising administering to said patient a radiolabeled anti-CD20 antibody.

8. (Currently amended) The method of Claim 7, wherein said radiolabeled anti-CD20 antibody is administered from about one week to about two years after said administration of said ~~ehimeric~~ anti-CD20 antibody.

9. (Currently amended) The method of Claim 8, wherein said radiolabeled anti-CD20 antibody is administered from about one week to about nine months after said administration of said ~~ehimeric~~ anti-CD20 antibody.

10-31. (Canceled)

32. (Currently amended) The method of claim 7, wherein the non-radiolabeled ~~ehimeric~~ anti-CD20 antibody is rituximab.

33. (Previously presented) The method of claim 7, wherein the radiolabeled anti-CD20 antibody is a murine anti-CD20 antibody.

34. (Previously presented) The method of claim 33, wherein the radiolabeled anti-CD20 antibody is 2B8.

35. (Currently amended) The method of claim ~~4~~ 7, wherein the radiolabeled anti-CD20 antibody is ⁹⁰Y-labeled anti-CD20.

36. (Currently amended) The method of claim ~~4~~ 7, wherein the radiolabeled anti-CD20 antibody is ¹³¹I-labeled anti-CD20.

GRILLO-LOPEZ -- Appl. No. 09/762,587
Attorney Docket No. 037003-0277847

37. (Currently amended) The method of claim 7, further comprising administering a B cell depleting amount of a non-radiolabeled ~~chimeric~~ anti-CD20 antibody to the subject prior to administration of the radiolabeled anti-CD20 antibody.

38. (New) The method of claim 32, wherein the radiolabeled anti-CD20 antibody is a murine anti-CD20 antibody.

39. (New) The method of claim 38, wherein the radiolabeled murine anti-CD20 antibody is ⁹⁰Y-labeled anti-CD20.

40. (New) The method of claim 38, wherein the radiolabeled murine anti-CD20 antibody is ¹³¹I-labeled anti-CD20.

41. (New) The method of claim 32, further comprising administering a B cell depleting amount of a non-radiolabeled anti-CD20 antibody to the subject prior to administration of the radiolabeled anti-CD20 antibody.

42. (New) The method of claim 32, wherein said radiolabeled anti-CD20 antibody is administered from about one week to about two years after said administration of said anti-CD20 antibody.

43. (New) The method of claim 32, wherein said radiolabeled anti-CD20 antibody is administered from about one week to about nine months after said administration of said anti-CD20 antibody.